Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background Oxyntomodulin has recently been found to decrease body-weight in obese humans and may be a potential anti-obesity therapy.Objective To determine whether oxyntomodulin alters energy expenditure, in addition to reducing energy intake, in 'free-living' overweight and obese volunteers.Design Randomized double-blind controlled cross-over trial.Setting Community and hospital-based.Participants Fifteen healthy overweight and obese men and women (age: 23-49 years, BMI: 25.1-39.0 kg/m(2)). All volunteers completed the study protocol.Interventions Four-day subcutaneous self-administration of pre-prandial oxyntomodulin, three times daily. Participants were advised to maintain their normal dietary and exercise regimen.Measurements (1) Energy expenditure, measured by indirect calorimetry and combined heart rate and movement monitoring; (2) energy intake, measured during a study meal.Results Oxyntomodulin administration reduced energy intake at the study meal by 128+/-29 kcal (P=0.0006) or 17.3+/-5.5% (P=0.0071), with no change in meal palatability. Oxyntomodulin did not alter resting energy expenditure; but increased activity-related energy expenditure by 143+/-109 kcal/day or 26.2+/-9.9% (P=0.0221); total energy expenditure by 9.4+/-4.8% (P=0.0454) and physical activity level by 9.5+/-4.6% (P=0.0495). A reduction in body weight of 0.5+/-0.2% was observed during the oxyntomodulin administration period (P=0.0232).Conclusion Oxyntomodulin increases energy expenditure while reducing energy intake resulting in negative energy balance. This data supports the role of oxyntomodulin as a potential anti-obesity therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oxyntomodulin activates the glucagon receptor and GLP-1 receptor and promotes weight loss through elevated energy expenditure and decreased energy intake in humans (Wynne et al, 2005(Wynne et al, , 2006)).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wynne et al, 2006
In the citing paper
“ACCORD, like the UKPDS, demonstrated that improved glucose control reduced microvascular complications126”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [126]
Citations
Cites
Obesity : Preventing and managing the global epidemic
Akram, D. S., Astrup, A. V., Atinmo, T., Boissin, J.-L., Bray, G. A., Carroll, K. N., Chitson, P., Chen, C., Dietz, W. H., Hill, J. O., et al. (2000) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 12,945
Prevalence of Overweight and Obesity Among US Children, Adolescents, and Adults, 1999-2002
Hedley, A. A. (2004) · JAMA · doi:10.1001/jama.291.23.2847 · Cited by 4,460
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Self-citationInhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Self-citationThe SCOFF questionnaire: Assessment of a new screening tool for eating disorders
Morgan, J. F., Reid, F., & Lacey, J. H. (1999) · BMJ · doi:10.1136/bmj.319.7223.1467 · Cited by 1,416
Role of Nonexercise Activity Thermogenesis in Resistance to Fat Gain in Humans
Levine, J. A., Eberhardt, N. L., & Jensen, M. D. (1999) · Science · doi:10.1126/science.283.5399.212 · Cited by 997
Reliability and validity of the combined heart rate and movement sensor Actiheart
Brage, S., Brage, N., Franks, P. W., Ekelund, U., & Wareham, N. J. (2005) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602118 · Cited by 667
Food Fails to Suppress Ghrelin Levels in Obese Humans
English, P. J. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.6.2984 · Cited by 534
Self-citationBrage, S., Brage, N., Franks, P. W., Ekelund, U., Wong, M.-Y., Andersen, L. B., Froberg, K., & Wareham, N. J. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00703.2003 · Cited by 473
Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans
Cohen, M. A., Ellis, S. M., Le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030421 · Cited by 472
Self-citation
Cited by
Items 301–365 of 365
Glucagon and the metabolic syndrome
Welch, A., & Vella, A. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00011-6 · Cited by 2
Ghrelin in Cachexia Associated with End-Stage Renal Disease
Ashby, D. R., Choi, P., & Bloom, S. R. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-903-7_13 · Cited by 2
“also involved in regulation of activity [ 116 ] .”
BackgroundSelf-citationIncretins: new targets for the prevention of diabetes and obesity
Neff, K., & le Roux, C. W. (2013) · Clinical Lipidology · doi:10.2217/clp.12.80 · Cited by 1
The Role of Central Nervous System Glucagon-Like Peptide-1 in the Regulation of Energy Balance
Barrera, J. G. (2009) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Hypothalamic Obesity and Wasting Syndromes
Uwaifo, G. I. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-030-62187-2_12 · Cited by 2
Development of a selective, sensitive and robust oxyntomodulin dual monoclonal antibody immunoassay
Umberger, T. S., Ming, W., Cox, J. M., Konrad, R. J., & Siegel, R. W. (2022) · Bioanalysis · doi:10.4155/bio-2022-0084 · Cited by 1
Adiponectin, Diabetes, and the Cardiovascular System
Gasbarrino, K., Boutari, C., Filippaios, A., Gianopoulos, I., Daskalopoulou, S. S., & Mantzoros, C. S. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_8 · Cited by 1
Sanetra, A. M., Palus‐Chramiec, K., Chrobok, Ł., Jeczmien‐Lazur, J. S., Klich, J. D., & Lewandowski, M. H. (2023) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2023.103873 · Cited by 3
“However, they are also potent satiety signals influencing behaviour (decreasing food intake), and metabolism (stimulating energy expenditure; Hwa et al., 1998, Dakin et al., 2001, 2002, Baggio et al., 2004, Osaka et al., 2005, Wynne et al., 2006, Pocai et al., 2009, Kosinski et al., 2012).”
BackgroundWoodard, J. (2010) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign) · Cited by 1
Obesity research: Status quo and future outlooks
Gammal, A. T. E. (2014) · World Journal of Translational Medicine · doi:10.5528/wjtm.v3.i3.119 · Cited by 1
The Gut and Type 2 Diabetes Mellitus
Boyce, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-28803-7_42 · Cited by 1
Gut Hormones and Metabolic Syndrome
Bhat, S. Z., Park, H. K., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_25 · Cited by 3
Kelesidis, T., Kelesidis, I., & Mantzoros, C. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-453-1_3 · Cited by 1
Gut as an Endocrine Organ: The Role of Nutrient Sensing in Energy Metabolism
Wang, M. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch1 · Cited by 1
Peptide YY and Oxyntomodulin novel gene therapy treatment for obesity
Cárdenas, A. (2006) · USFQ Digital Repository (Universidad San Francisco de Quito) · Cited by 1
Food Intake, Circuitry, and Energy Metabolism
Yeo, G. S. H. (2016) · Wiley eBooks · doi:10.1002/9781118760369.ch16 · Cited by 1
Mercado, C. I. (2012) · ResearchWorks at the University of Washington (University of Washington) · Cited by 1
Adjunctive Therapy, Including Pharmacotherapy
Al-Bazz, D. Y., & Wilding, J. P. H. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch21 · Cited by 1
Gastrointestinal Hormones and Obesity
Wang, Y., & Kokkotou, E. G. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1607-5_6
Obesity Insulin Resistance and Gut Hormones
Proietto, J. (2009) · Wiley eBooks · doi:10.1002/9781444307627.ch14
Metabolic Synchronization of the Liver Circadian Clock
Landgraf, D., Drucker, D. J., & Oster, H. (2011) · The Endocrine Society eBooks · doi:10.1210/endo-meetings.2011.part2.p8.p1-488
The role of short chain fatty acids in appetite regulation
Psichas, A. (2013) · doi:10.25560/23364 · Cited by 1
Hormones and Gastrointestinal Function
Prodam, F., Bellone, S., Savastio, S., Busti, A., Guidi, C., Monzani, A., & Bona, G. (2012) · Springer eBooks · doi:10.1007/978-88-470-1405-3_43
Modulació farmacològica de l'oleoil-estrona sobre la ingesta i la composició corporal
Lorente, R. F. (2007) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Boguszewski, C. L., Paz-Filho, G., & Velloso, L. A. (2010)
Scott, J. D. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.02.028
Ansätze wider den großen Appetit
Mai, K. (2016) · Info Diabetologie · doi:10.1007/s15034-016-0839-7
“Dementsprechend fand sich nach regelmäßiger subkutaner Applikation von OXM über 4 Tage eine 17%ige Reduktion der Energieaufnahme und bereits eine Gewichtsreduktion von 0,5% [27].”
BackgroundNusbaum, M. J., Rothkopf, M. M., & Haverstick, L. P. (2014) · CRC Press eBooks · doi:10.1201/b17616-5
Appetite and metabolic responses to acute and moderate-term dairy snack consumption in young people
Green, B. (2015) · Northumbria Research Link (Northumbria University)
The preproglucagon derived peptides and energy homeostasis
Parker, J. (2013) · doi:10.25560/10956
The Genetic Mechanisms Underlying Human Obesity
Clark, S. J. (2012) · doi:10.25560/11607
The role of gut hormones on food intake and carbohydrate tolerance
Tharakan, G. (2016) · Spiral (Imperial College London) · doi:10.25560/41846
“1 Weight loss OXM causes weight loss in humans and rodents(131,135-138).”
BackgroundSim, Y., Park, S.-H., Kim, S., Lee, J.-R., Jung, J., Sharma, N., & Suh, H. (2017) · Neurochemical Journal · doi:10.1134/s1819712416040115
Targeting the intestinal L-cell for obesity and type 2
Wewer, N. J., Kuhre, R. E., Deacon, C. F., & Holst, J. J. (2014)
Medina, A. L. B. (2017) · Universidad San Ignacio de Loyola · doi:10.20511/usil.thesis/2906
Developmental Origins and Roles of Intestinal Enteroendocrine Hormones
Jonnakuti, V. S., Stanescu, D. E., & León, D. D. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814823-5.00035-0
Neto, A., & de, H. A. (2006) · Americanae (AECID Library)
OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetesPreprint
Kayed, A., Melander, S. A., Andreassen, K. V., Karsdal, M. A., & Henriksen, K. (2021) · Research Square · doi:10.21203/rs.3.rs-223237/v1
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Development of protocols to identify high hunger and low satiety phenotypes
Elfarssi, H. M. (2019) · Sheffield Hallam University · doi:10.7190/shu-thesis-00370
Mechanisms of Action of Different Bariatric Surgical Procedures
Neff, K., & le Roux, C. W. (2021) · Springer eBooks · doi:10.1007/978-3-030-54064-7_103-1
Hormones and Gastrointestinal Function of Newborns
Prodam, F., Bellone, S., Ricotti, R., Monzani, A., Genoni, G., Giglione, E., & Bona, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-29489-6_184
Vakilgilani, T., Zac‐Varghese, S., & Bloom, S. R. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1203-2_3
Self-citation(2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f4f084
Glucagon and the Glucagon-Like Peptides
Drucker, D. J. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00035-6
Metabolic synchronization of the liver circadian clock
Landgraf, D. (2012) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1435
Damasceno, R. C., Oliveira, F. R., Cândido, A. L., Gomes, K. B., Bizzi, M. F., Azevedo, R. C., Comim, F. V., dos Reis, F. M., & Rocha, A. L. L. (2023) · Research Square · doi:10.21203/rs.3.rs-2375448/v1
Damasceno, R. C., de Oliveira, F., Cândido, A. L., Gomes, K. B., Bizzi, M. F., Azevedo, R. C., Comim, F. V., dos Reis, F. M., & Rocha, A. L. L. (2023) · Research Square · doi:10.21203/rs.3.rs-2996959/v1
Gut Hormones and Metabolic Syndrome
Bhat, S. Z., Park, H. K., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_25-2
Multi‐target Peptides for the Treatment of Metabolic Diseases
Bossart, M., & Heßler, G. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch20
Damasceno, R. C., Oliveira, F. R., Cândido, A. L., Gomes, K. B., Bizzi, M. F., & Rocha, A. L. L. (2025) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0451
“Nonetheless, OXM or its pharmacological analogues may still play a role in treating obesity, insulin resistance, and glucose intolerance (5,6), offering potential benefits for a significant subset of women with PCOS who also suffer from these comorbidities.”
Jinhua, Z., & Li, R. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5376321
Molecular and cellular targets in the management of metabolic diseases and disorders: An overview
Cariño‐Cortés, R., Isabel, S.-C. M., Antonio, E.-D. J., Luis, J.-S., Fernández‐Martínez, E., & Fernanda, V.-C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00004-4
Shestakova, E. A., Томилова, А. О., Samsonova, M. D., Voznesenskaya, А. А., Sineokaya, M. S., Stafeev, I., & Shestakova, M. V. (2025) · Diabetes Mellitus · doi:10.14341/dm13267
Deighton, K. (2013) · Loughborough University Institutional Repository (Loughborough University)
Halquist, M. S. (2012) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/wv5y-t454
Jin, Z., Li, J., Thackray, A. E., King, J. A., Mould, C., & Stensel, D. J. (2026) · Appetite · doi:10.1016/j.appet.2026.108541 · Cited by 1
The association between glucose dynamics and energy intake in young, healthy women
Jin, Z., Thackray, A. E., Willis, S. A., King, J. A., Li, J., Mould, C., & Stensel, D. J. (2026) · European Journal of Clinical Nutrition · doi:10.1038/s41430-026-01727-0
“Studies also have highlighted the role of oxyntomodulin (OXM) in appetite regulation [28, 29].”
Regulators of appetite in mammals—old and new players
Fernandes, J. H., Silva, J. D., Costa, M. D., & Maciel, P. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag020 · Cited by 1
Han, S., Shin, J., Kim, J. C., & Na, D. H. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00815-4
“Oxyntomodulin is an endogenous peptide hormone that acts as an agonist at both the GLP-1R and glucagon receptor (GCGR) (Zimmermann et al. 2022), thereby mediating meaningful weight reduction and increased energy expenditure through its dual agonist activity (Wynne et al. 2005, 2006).”
Hsia, S. H., Bays, H. E., Billings, L. K., Weideman, A. M., Mather, K. J., Coşkun, T., Haupt, A., Thomas, M. K., Tham, L. S., Calderón, B., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00160-9 · Cited by 1
BindingDB (2014) · UC San Diego · doi:10.7270/q2pk0hmz
From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism
Saldívar-Cerón, H. I., Maldonado-Trejo, D., Chavez-Castañeda, Q., Mercado-Guzmán, A. L., León-Barrita, A. D. J., López-García, I. A., Hernández-Solís, A., Ramírez-Mendoza, A. M., Terrazas-Delgado, D. A., Castañeda-Ramírez, A. E., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219654 · Cited by 1
Metadata
- Authors
- Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R.
- Affiliations
- Hammersmith Hospital (GB)
- Corresponding author
- Bloom, S R
- Venue
- International Journal of Obesity
- Published
- 2006-04-18
- Volume
- 30
- Issue
- 12
- Pages
- 1729-1736
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W2135978651
- Cited by
- 363
- References
- 32
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 14 · 2023: 22 · 2022: 15 · 2021: 22 · 2020: 18 · 2019: 14 · 2018: 21 · 2017: 15 · 2016: 20 · 2015: 16 · 2014: 21 · 2013: 32 · 2012: 24
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- oxyntomodulin, energy expenditure, energy intake, obesity, overweight, obesity treatment, physical activity, weight loss, negative energy balance, GLP-1 receptor agonists
- MeSH terms
- Adult, Blood Pressure, Energy Intake, Double-Blind Method, Energy Metabolism, Female, Heart Rate, Humans, Injections, Subcutaneous, Insulin, Male, Middle Aged, Obesity, Self Administration, Body Mass Index, Cross-Over Studies, Anti-Obesity Agents, Overweight, Oxyntomodulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.